Table 1 Clinicopathological characteristics of patients receiving NACT

Age (years), median (IQR)

52.00 (50.00, 61.75)

59.00 (51.00, 65.00)

0.028

BMI (kg/m²), median (IQR)

22.50 (20.26, 24.20)

22.42 (20.55, 25.19)

0.415

CCI

0.553

 0

47 (81.0%)

93 (86.1%)

 1

5 (8.6%)

9 (8.3%)

  > = 2

6 (10.3%)

6 (5.6%)

ECOG score

0.41

 0

32 (55.2%)

48 (44.4%)

 1

24 (41.4%)

53 (49.1%)

 2

2 (3.4%)

7 (6.5%)

Hydrothorax^a

0.795

 Yes

7 (12.1%)

11 (10.2%)

 No

51 (87.9%)

97 (89.8%)

Ascites^a

0.005

 Yes

17 (29.3%)

57 (52.8%)

 No

41 (70.7%)

51 (47.2%)

CA125^a, median (IQR)

1429.0 (504.58, 3028.75)

1187.0 (609.80, 2935.50)

0.598

Pathology type

0.721

 Serous

54 (93.1%)

103 (95.4%)

 Non-serous

4 (6.9%)

5 (4.6%)

FIGO stage

0.001

 IIIC

29 (50.0%)

83 (76.9%)

 IV

29 (50.0%)

25 (23.1%)

SCS

0.004

 Low

6 (10.3%)

31 (28.7%)

 Intermediate

52 (89.7%)

73 (67.6%)

 High

0 (0.0%)

4 (3.7%)

BRCA mutation^b

0.419

 Yes

11 (19.0%)

31 (28.7%)

 No

29 (50.0%)

55 (50.9%)

 Missing

18 (31.0%)

22 (20.4%)

NACT cycles

0.659

  < = 2

29 (50.0%)

60 (55.6%)

 3

24 (41.4%)

37 (34.3%)

  > = 4

5 (8.6%)

11 (10.2%)

NACT-IDS interval (days)^c, mean (IQR)

29.00 (25.00, 36.50)

29.50 (24.75, 35.25)

0.995

Chemotherapy Lines before first PRR^d

0.307

 1

11 (19.0%)

11 (10.2%)

 2

4 (6.9%)

4 (3.7%)

  > = 3

3 (5.2%)

0 (0.0%)

 Unknown

40 (69.0%)

93 (86.1%)